A sensitive high-performance capillary zone electrophoresis (CZE) with head-column field-amplified sample stacking (FASS) in binary system has been developed for the simultaneous determination of zotepine and its active metabolite, norzotepine, in human plasma. The separation of zotepine and norzotepine was performed using a background electrolyte consisting of 50% ethylene glycol-borate buffer (20mM, pH 8.0) solution with 20% methanol as the running buffer and on-column detection at 200 nm. Under the optimal FASS-CZE condition, good separation with high efficiency and short analysis time is achieved. Several parameters affecting the separation and sensitivity of the drug were studied, including sample matrix, pH and concentrations of the borate buffer, ethylene glycol and methanol. Using clozapine as an internal standard, the linear ranges of the method for the determination of zotepine and norzotepine in human plasma were over 3-100 ng/mL; the detection limits of zotepine and norzotepine in plasma were 2 and 1 ng/mL, respectively. A sample pretreatment by means of solid-phase extraction (SPE) with subsequent quantitation by FASS-CZE was used. The application of the proposed method for determination of zotepine and norzotepine in plasma collected after oral administration of 125 mg zotepine in one schizophrenic patient was demonstrated.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.chroma.2004.11.061 | DOI Listing |
J Pharmacol Exp Ther
June 2010
Pharmacology Research Laboratories, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan.
The antipsychotic drug zotepine [ZTP; 2-[(8-chlorodibenzo[b,f]thiepin-10-yl)oxy]-N,N-dimethylethan-1-amine] is known to have not only atypical antipsychotic effects but also antidepressive effects in schizophrenia patients. Norzotepine [norZTP; N-desmethylzotepine, 2-[(8-chlorodibenzo[b,f]thiepin-10-yl)oxy]-N-methylethan-1-amine] has been postulated to be a major metabolite of ZTP in humans. Here, we characterized norZTP through several in vitro studies and in animal models of psychosis, depression, and extrapyramidal symptoms (EPS) and compared the pharmacological profiles with those of ZTP.
View Article and Find Full Text PDFJ Chromatogr A
September 2005
Graduate Institute of Pharmaceutical Sciences, Kaohsiung Medical University, Kaohsiung 807, Taiwan.
A sensitive high-performance capillary zone electrophoresis (CZE) with head-column field-amplified sample stacking (FASS) in binary system has been developed for the simultaneous determination of zotepine and its active metabolite, norzotepine, in human plasma. The separation of zotepine and norzotepine was performed using a background electrolyte consisting of 50% ethylene glycol-borate buffer (20mM, pH 8.0) solution with 20% methanol as the running buffer and on-column detection at 200 nm.
View Article and Find Full Text PDFDrug Metab Pharmacokinet
March 2005
Biopharmaceutical and Pharmacokinetics Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan.
TSQ ESI MS/MS and ion trap ESI MS(2) cleave protonated molecules. MS(2) at m/z 332 of zotepine cleaved m/z 245 (10%), m/z 287 (5%) and m/z 315 (100%) fragment ions at protonated positions. MS(2) at m/z 356 of tiaramide cleaved m/z 338 (18%), 313 (10%), 226 (100%), 198 (78%) and 131 (60%) fragment ions at protonated positions.
View Article and Find Full Text PDFXenobiotica
March 1999
Biopharmaceutical and Pharmacokinetic Research Laboratories, Fujisawa Pharmaceutical Co., Ltd, Osaka, Japan.
1. Studies using human liver microsomes and recombinant human cytochrome P450 (P450) enzymes and flavin-containing monooxygenase (FMO) were performed to identify the enzymes responsible for the formation of zotepine metabolites in man. 2.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!